

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2928577

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT	
<b>EFFECTIVE DATE:</b>	05/02/1998	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ARTHUR FRANKEL	06/04/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	WAKE FOREST UNIVERSITY HEALTH SCIENCES	
<b>Street Address:</b>	MEDICAL CENTER BOULEVARD	
<b>City:</b>	WINSTON-SALEM	
<b>State/Country:</b>	NORTH CAROLINA	
<b>Postal Code:</b>	27157	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	13884899
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	elissa.russell@nortonrosefulbright.com	
<b>Correspondent Name:</b>	NORTON ROSE FULBRIGHT	
<b>Address Line 1:</b>	98 SAN JACINTO BLVD	
<b>Address Line 2:</b>	STE 1100	
<b>Address Line 4:</b>	AUSTIN, TEXAS 78701	
<b>ATTORNEY DOCKET NUMBER:</b>	SCOT.P0012US	
<b>NAME OF SUBMITTER:</b>	ELISSA RUSSELL	
<b>SIGNATURE:</b>	/Elissa Russell/	
<b>DATE SIGNED:</b>	07/08/2014	
<b>Total Attachments: 3</b>		
source=Scot12NuncProTunc#page1.tif		
source=Scot12NuncProTunc#page2.tif		
source=Scot12NuncProTunc#page3.tif		

### NUNC PRO TUNC ASSIGNMENT

I, Arthur E. Frankel, of 9435 Monteleon Court, Dallas, Texas 75220, a citizen of the United States, am a joint inventor of an invention entitled "ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8" as described in the patent applications set forth in Table 1 (the "Invention"). My inventive contribution to the Invention was initiated while I was in the employ of Wake Forest University Health Sciences ("Wake Forest") from May 2, 1998 to June 30, 2005 and continued during my employment with Scott & White Clinic (having a place of business at 2401 S. 31<sup>st</sup> St., Temple, Texas 76508), an affiliate of Scott & White Healthcare, from July 1, 2005 to February 1, 2013. While employed at Scott & White Clinic, I was subject to the policies of Scott & White Healthcare, including the intellectual property policies of Scott & White Healthcare.

On November 28, 2011, in accordance with the intellectual property policy of Scott & White Healthcare, I assigned to Scott & White Healthcare ("Scott & White") my full and exclusive right, title and interest in and to the Invention, throughout the world, including the United States and its territorial possessions and in all foreign countries, including all rights to claim priority, in and to any and all improvements which are disclosed in said application. This includes an assignment of all Letters Patent that may be granted on the invention in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reexamination, reissue, prolongation or extension thereof; and the right to claim priority from the patent application as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law. I am advised that this assignment is recorded at the US PTO at Reel/Frame 031949/0434.

I now understand that rights in any inventions I conceived or reduced to practice while I was in the employ of Wake Forest were owned by Wake Forest by virtue of my employment by Wake Forest, and that the November 28, 2011 assignment to Scott & White was effective only to assign my rights in the Invention conceived or reduced to practice after I became employed by Scott & White Clinic in 2005. I am therefore executing the present Nunc Pro Tunc Assignment to document and verify the ownership by Wake Forest of those aspects of the Invention I invented while employed by Wake Forest.

THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, I hereby:

SELL, ASSIGN AND TRANSFER to Wake Forest University Health Sciences (the "Assignee"), having a place of business at Medical Center Boulevard, Winston-Salem, North Carolina 27157, my entire right, title and interest in those aspects of the Invention, embodied in one or more of the patent applications in Table 1, that I invented while in the employ of Wake Forest University Health Sciences from May 2, 1998 to June 30, 2005, throughout the world, including the United States and its territorial possessions and in all foreign countries, including all rights to claim priority, in and to any and all improvements which are disclosed in said

applications. This includes an assignment of all Letters Patent that may be granted on the invention in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reexamination, reissue, prolongation or extension thereof; and the right to claim priority from the patent application as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

These provisions are binding upon my heirs, assigns, representatives and successors and assigns.

The assignment of said invention is effective as of the date of execution shown below.

Signature: [Signature]  
Name: Arthur E. FRANKEL

Date: 6/4/2014

STATE OF Texas  
COUNTY OF Dallas

BEFORE ME, the undersigned authority, on this 4 day of June, 2014 personally appeared Arthur E. FRANKEL, known to me to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he/she executed the same of his/her own free will for the purposes and consideration therein expressed.

Rosemary Vega  
Notary or Consular Officer

[SEAL]




TABLE I

"ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8"			
Country	Type	Application No.	Filing Date
U.S.	Provisional	61/412,999	11/12/2010
U.S.	Provisional	61/527,339	8/25/2011
PCT	PCT	PCT/US2011/060583	11/14/2011
U.S.	Utility	13/884,899	5/10/2013
Europe	PCT	11840238.7	11/14/2011